未经治疗的甲状腺功能亢进型格雷夫斯病患者血清中促甲状腺激素结合抑制性免疫球蛋白的异质性。
Heterogeneity of thyrotropin binding inhibitor immunoglobulins in serum from untreated patients with hyperthyroid Graves' disease.
作者信息
Lu C, Kasagi K, Iida Y, Konishi J
机构信息
Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
出版信息
Immunol Lett. 1991 Jun;28(3):233-6. doi: 10.1016/0165-2478(91)90009-y.
We have previously established an assay for the simultaneous assessment of thyrotropin (TSH) binding inhibitor immunoglobulin (TBII) and thyroid stimulating autoantibody activities in cultured rat thyroid cells (FRTL-5 cell), and found a discrepancy in some patients with untreated Graves' disease between the activities of TBII measured in FRTL-5 cells (TBII-rc) and in solubilized thyroid membranes (TBII-pm). In three selected patients with untreated Graves' disease, the different dose-response relationship between TBII-rc and TBII-pm clearly indicated the heterogeneous populations of TBII-pm in patients' sera, with different binding affinities for TSH receptor in intact cells.
我们之前建立了一种用于同时评估促甲状腺激素（TSH）结合抑制性免疫球蛋白（TBII）和甲状腺刺激自身抗体活性的检测方法，该方法用于培养的大鼠甲状腺细胞（FRTL-5细胞），并且发现在一些未经治疗的格雷夫斯病患者中，FRTL-5细胞中测得的TBII活性（TBII-rc）与溶解的甲状腺膜中测得的TBII活性（TBII-pm）之间存在差异。在三名选定的未经治疗的格雷夫斯病患者中，TBII-rc与TBII-pm之间不同的剂量反应关系清楚地表明了患者血清中TBII-pm的异质性群体，其对完整细胞中的TSH受体具有不同的结合亲和力。
Zotero 插件